initi coverag soon renam viatri neutral rate
pt certainli lost us new entiti combin myl/upjohn
entiti fundament differ compani render myl retail gener
segment less import overal mix viatri pro forma
pf revenu someth said geograph diversif
said well pro forma pf ebitda come larg off-pat brand
global along major exposur evolv challeng chines market
visibl sustain ebitda murki beyond though applaud manag
effort regard biosimilar pegfilgrastim complex gener advair
competit dynam challeng add current pf ebitda
multipl view posit expand
cover myl/viatri differ compani differ leadership
caveat histor weve admittedli hesit jump feet
debat one polar name polar space bumpi ride
say least public relat drama surround epipen price pursuit
cover busi mix leadership pois
transform chang tend believ transpar improv
polar surround new entiti ebb extent howev
mean viatri start trade richer valuat anytim soon challeng
us visibl ebitda durabl given view almost axiomat
matur larg off-pat brand account near pf revenu
time experi signific sale margin compress
good news retail market gener fairli small part ebitda
mix estim gener account pf corpor
ebitda go forward addit upjohn greenston gener
unit new entiti import epipen continu wane competit
dynam overal howev real challeng instanc myl advair gener
underwhelm view given aggress glaxo play defens
weve seen dynam play copaxon gener expect kind
dynam case complex gener restasi biosimilar
bad news revenu concentr global revenu upjohn
gener top five sell brand exclud sale lyrica
lost exclus juli lyrica also lose exclus japan decemb
around total upjohn revenu first nine month
gener greater china mostli lipitor norvasc kind geograph
diversif desir doubt
risk includ pricing/competit risk generics/biosimilars/matur brand
one world lead gener drug compani
forma ev/ebitda
assum debt cash
share outstand disc
one year
debt total capit
piper sandler seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
matur
initi coverag neutral rate pt repres downsid
current share price bulk pro forma pf corpor ebitda
come sourc outsid gener along grow complex generics/biosimilar
platform newco name viatri certainli look like garden varieti gener
compani said new busi mix view translat higher visibl
durabl pf ebitda quit contrari believ real risk sustain pf
ebitda per manag guidanc function realiti well
estim pf corpor ebitda
brand manag also guid pf ebitda margin around sustain
context segment unprotect brand market pressur view matter
doubt add current ev/ebitda multipl
view posit expand much though acknowledg pf net debt ratio
problemat particularli rel major gener peer group estim pf net
ebitda around view give viatri leadership team good
deal bandwidth execut addit consequenti consequenti mean
addit truli durabl asset view anytim soon pt base
ebitda multipl pf ebitda estim discount one year
support discount cash flow dcf analysi new entiti see
viatri provid whole lot geograph diversif price hint revenu
concentr gener includ greenston unit upjohn shouldnt account
pf corpor revenu go forward shouldnt account
pf corpor ebitda go forward certainli bit good news context
retail gener space becom increasingli commodit though price eros
moder almost steady-st pace day way obscur realiti
commodit clear fact life retail gener space myl ostens
answer conundrum commodit lean brand asset lean geograph
diversif vacuum that commend said top five sell product
upjohn busi global account total upjohn revenu first nine month
per even exclud lyrica product lost exclus juli
top five seller still account upjohn global revenu first nine
month asid total upjohn revenu account near total
revenu new entiti manag guid pf revenu new entiti
one hand transact drive diversif away retail market
gener lean greater geograph diversif hand creat
revenu ebitda concentr risk make matter wors concentr risk
call associ product higher margin brand
worri china per around total upjohn revenu first nine
month gener greater china note time period
greater china revenu two time higher emerg market revenu
specif combin lipitor norvasc sale greater china annual
base sale first nine month beyond chines govern roll
new expand tender system sale volum may guarante
lowest three bidder actual four bidder per pilot phase
program expand program cover greater number region greater china upjohn
note success first bid process final past septemb
note contract mostli went china-bas gener compani chines
gener industri eventu come speak would expect see
pressur price result new tender process road put anoth way
difficult time envis dynam translat meaning potenti
signific pressur corpor pro forma revenu ebitda intermediate-to-long
 gener still matter perform complex product underscor tough
competit realiti note estim retail gener account
pf corpor ebitda go forward addit pfizer
page
greenston gener unit part transact import epipen continu
declin whole applaud manag focu complex gener product
term approv least major win said competit dynam
real challeng instanc myl advair gener known wixela inhub
first substitut gener version advair disku glaxo report sale around
someth disappoint view given aggress glaxo
play defens recal advair gener launch februari week
end myl share advair market volum per iqvia stood week
third parti data market consist wixela brand prasco author gener
ag suggest quarterli run rate wixela sale neighborhood
undoubtedli import product fairli underwhelm consid first-to-
market ftm gener blockbust product weve seen kind dynam play
copaxon gener expect kind dynam case complex
gener see wixela complex gener underscor two
challeng realiti innov compani aggress play defens face
loss exclus loe situat mainli aggress play payer contract game
extent limit gener competit power buyer consortium
mean even rel limit competit environ price destruct still quit
signific put anoth way dynam essenti dilut valu pipelin
complex gener product certainli phenomenon uniqu
undoubtedli made real progress build biosimilar footprint
competit realiti also bear watch recal june along partner
biocon base india becam first compani gain fda approv biosimilar neulasta
pegfilgrastim product known fulphila launch juli case
complex gener competit dynam regard biosimilar undoubtedli challeng
bear mind coheru cover launch pegfilgrastim biosimilar known
udenyca januari note coheru report net sale
product suggest recent quarterli run rate fulphila
neighborhood though manag believ overal footprint pegfilgrastim biosimilar
grow view necessarili translat grow revenu footprint
myl product bear mind sandoz pegfilgrastim biosimilar known ziextenzo
gain fda approv novemb put anoth way market becom crowd
price pressur becom consider kind dynam
certainli bear watch myl latest entri broader biosimilar space recent
launch herceptin trastuzumab biosimilar known ogivri manag note recent
plan environ consist around competitor
price
debt cash certain compani may may pro forma reflect major cash inflows/outflow pending/rec complet transact
valu market cap debt cash ev base psc dcf estim
psc estim factset compani report
page
except per share multipl markettotaltotal p/eev/ebitdatickercompanypric capdebtcashvalu mylan peer exhibit
ev equiti valu per share calcul use termin growth rate top wacc left assumpt
includ cash cash equival short long term market secur
compani report psc estim
compani report psc estim
page
free good develop gener administr incom depreci ebitda margin oper provis incom oper depreci capit increas net work cash valu cash valuationfranchis enterpris valu growth cash cash termin valu per share dilut share outstand valu per except per
summari psc estim stand-alone
consensu estim
factset psc estim
price target new entiti base pro forma ebitda estim
time ev/ ebitda multipl discount one year base pt
ebitda estim given reflect full impact transact expect close
though conced fulli reflect synergi captur compani
note expect realiz total synergi also note
also fulli reflect full extent potenti pressur off-pat brand distribut
upjohn case point lyrica goe patent japan decemb also note
pf ebitda estim reflect signific contribut new gener launch
 restasi gener rel limit competit reflect estim
signific contribut biosimilar signific contribut herceptin biosimilar
ogivri start
given view combin entiti good visibl sustain ebitda
believ ebitda multipl appropri best base part multipl
compar major gener compani valu new entiti discount
group mean nod fact viatri pro forma leverag ratio
problemat pf total debt close net ebitda around
valuat conclus support discount cash flow dcf analysi new
entiti see detail note senior manag guid annual
pf revenu annual pf ebitda
page
million except per current current current current current north revenuetot gener administr margin tax exhibit
ev equiti valu per share calcul use termin growth rate top wacc left assumpt
compani report psc estim
compani report psc estim
page
free total brand gener total viatri good develop gener administr incom depreci ebitda margin oper provis incom oper depreci capit increas net work cash valu cash valuationenterpris valu growth cash cash termin valu pro total debt pro dilut share outstand pro valu per viatri except per share guidanceestimatespro forma forma adjust forma ebitda exhibit
summari psc estim new entiti
psc estim factset bloomberg compani report
juli pfizer upjohn enter agreement merg form viatri
part agreement newli form entiti make cash payment
total debt sharehold outstand share
viatri common stock sharehold outstand share common
stock fulli dilut basi transact expect close sometim
combin entiti global manufactur site oral solid dosag osd site steril
inject site site focus addit complex dosag form activ pharmaceut
page
million except per current current current current mylannorth brand gener margin gener administr margin tax
pf revenu mix base geographi new compani follow conced
wide rang best estim base inform
 estim account roughli pf revenu
emerg market geograph segment account roughli
pf revenu new entiti
greater china greater china area account roughli pf
revenu new entiti come lipitor norvasc
develop market geograph segment europ account
roughli pf revenu bear mind stand-alon myl
european segment nearli larg stand-alon entiti north american
quick take long-term prospect combin busi though core idea
transact vacuum logic diversif away gener diversif
brand asset geograph diversif realiti view upjohn core brand
busi provid kind cash flow durabl enabl meaning
sustain valu recoveri holder exposur china
evolv tender system also function realiti upjohn core
brand patent protect across myriad geographi mean
competit across rang region inevit product like lipitor norvasc
celebrex essenti commod wouldnt dynam repeat
time market put anoth way believ matter time asset
commodit across myriad territori
commerci risk price competit gener space particularli
undoubtedli felt sting increas commodit given consolid buyer
power consortium given faster pace gener approv particularli compani
base india fda work clear review backlog expect challeng
price trend continu though conced dynam nearli difficult
past year howev mean pace price eros acceler
acceler price eros could pressur margin ebitda way
greater current reflect estim
new entiti key brand face also face fair share commerci risk particularli given
fact brand product larg off-pat recent roll-out
expand tender system china like put ad pressur key brand name lipitor
norvasc could see greater expect margin ebitda pressur result
commerci dynam prove wors reflect estim
clinic regulatori risk signific driver futur revenu abil combin entiti
develop commerci rang complex gener biosimilar brand biosimilar
complex gener inher challeng develop regulatori perspect
delay timelin approv could significantli impact revenu ebitda given year
legal risk subject litig regard price collusion/infl outcom
proceed much uncertain also portfolio gener opioid product
subject litig relat opioid crisi though believ exposur
case limit sinc way signific brand player opioid space
page
merger integr risk combin busi segment associ format
viatri may fail produc kind synergi manag guid smaller
expect cost synergi effici could neg impact margin ebitda
one lead gener compani world year transform
diversifi pharmaceut compani signific global brand over-the-
counter over-the-counter presenc compani approxim product distribut
countri manufactur facil puerto rico addit
facil countri includ india australia japan compani signific activ
pharmaceut ingredi api capabl api facil addit abil produc oral
solid facil devot oral solid inject facil focus inject
transderm facil dedic complex product includ transderm topic
agent inhal product compani biosimilar busi larg partner-driven mylan
three differ report segment north america europ rest world row north
america primarili compani made signific stride develop
commerci complex gener product
brief overview recent dynam addit one largest distributor
oral solid gener product commodit end gener busi
distribut rang complex dosag form includ rang topic
inject recent inhal product estim north america
busi segment account total stand-alon revenu
estim sale north american segment rel flat compar
show low-singl digit growth versu regard larg function
new launch name contribut advair gener grow annual
contribut pegfilgrastim biosimilar fulphila coupl appear less
bad retail price environ rel recent year estim reflect
continu type retail price dynam coupl contribut addit
signific launch model reflect inclus restasi gener rel limit
competit environ well grow contribut trastuzumab biosimilar known
ogivri
brief overview recent dynam european segment europ oper
subsidiari across around differ countri mylan european busi
segment record net revenu revenu first
three quarter revenu european segment decreas versu
period pressur european segment off-set extent
avail hulio compani biosimilar abbvi humira launch product
europ octob
european gener market vari significantli countri exampl certain countri
germani character higher gener penetr typic
hand countri itali franc gener penetr low
hold leadership posit sever top ten gener market europ includ
number one two posit franc itali respect
rest world busi outsid europ distribut pharmaceut
approxim countri includ india australia japan new zealand india mylan
one largest api manufactur sever api intermedi facil australia
market lead gener posit compani japan segment also signific
driver row segment given enter partnership agreement pfizer japan
wherebi parti collabor gener product
page
epipen import overal busi continu declin still
consequenti product notabl accord third parti sale data iqvia epipen
specif myl author gener compani largest sell gener product
contribut still consequenti given hand-wring myl past price
action rais product price reduct part gestur good corpor
citizenship epinephrin auto-injector space still much limit competit environ
teva substitut gener product market
teva product gain fda approv august week end teva share
epinephrin auto-injector volum stood includ amneal adrenaclick
substitut product myl volum share stood includ
adrenaclick teva cite peak share target around end exclud
adrenaclick present know pend file substitut epipen gener
product entir surpris given drug/devic combin use
emerg set major pediatr popul compon popul fda
would understand uniqu sensit
regard adrenalick product expect experi signific share gain
injector devic differ epipen notori difficult
manufactur difficult enough period suppli constraint note pfizer
manufactur adrenaclick asid myl injector devic also experienc suppli issu
specif suppli issu began may also manufactur injector devic
page
copaxon competit dynam bear watch recal octob gain fda
approv substitut gener version mg/ml mg/ml dose copaxon
glatiram acet inject treatment multipl sclerosi first compani
gain fda approv gener version mg/ml dose account bulk weekli
total copaxon prescript note sandoz launch mg/ml dose june
ahead though import gener anoth one complex
product feel like better said teva undoubtedli play
defens fairli well sinc lost exclus aggress price contract
well payer certainli dynam see large-sel brand
lost exclus competit still rel limit innov compani
aggress defend share
note myl copaxon gener compani fourth largest sell gener
product per iqvia sale account around total iqvia-report gener sale gross
sale term volum share copaxon rx stood end
compar teva volum share note begin volum
share stood key overarch question surround copaxon go forward
extent see addit entrant clear believ new competit
matter vein amneal overweight manag recent
public comment note degre confid gener form copaxon could
gain approv know hand gener filer product well
page
brand author gener amneal adrenaclick tevaothervolum seq annualvolum seq annualvolum seq volum exhibit
brand gener copaxon prescript mg/ml mg/ml
advair gener perform underwhelm given size underli market prime
exampl challeng face complex gener point exampl
copaxon gener innov compani aggress defend share face
loss exclus major product aggress price/play payer
contracting/reb game anoth challeng element power buyer consortium
mean even limit competit environ price destruct still quit
signific experienc challeng dynam advair
gener put anoth way dynam essenti dilut valu pipelin complex
gener product certainli phenomenon uniqu
gain fda approv advair fluticason propion salmeterol inhal powder
gener known wixela inhub februari wixela becam first gener version
advair disku enter market week end myl share advair market
page
volum per iqvia stood week third parti data suggest previous
quarterli run rate wixela sale neighborhood gsk report sale
around undoubtedli import product underwhelm consid
first-to-market gener blockbust product competit front sandoz hikma
also purs approv gener version product experienc
setback regulatori process fda face share issu get
product finish line surpris given drug combin devic product
certainli complex definit note hikma submit respons fda
novemb follow receipt complet respons letter sandoz also
receiv earli
levothyroxin market particip levothyroxin sodium tablet gener
space time accord iqvia product myl second largest sell gener
 levothyroxin commerci avail sinc treatment
hypothyroid prior levothyroxin unapprov drug fda priorit
bring product modern era along defin path market ab-rat gener
page
levothyroxin market one uniqu dynam oral solid given dose
highli individu illustr point levothyroxin avail differ dosag
strength specif levothyroxin narrow therapeut index mean small
differ therapeut dose dose unaccept toxic
associ whole host drug-drug interact ddi given narrow therapeut window
risk advers event associ make minor chang patient dose regimen
difficulti find therapeut dose well-toler get thyroid hormon
optim level certain degre loyalti call sticki among patient
levothyroxin product highlight joint statement american thyroid
associ endocrin societi american associ clinic endocrinologist
state patient maintain brand name levothyroxin product
brand levothyroxin medic chang either one brand anoth brand
brand gener product gener product anoth gener product patient
re-evalu retest measur serum tsh thyroid stimul hormon six week
drug re-titr need given dynam surpris
gener market even though levothyroxin avail decad
current oral levothyroxin sodium market consist four brand market particip name
abbvi synthroid akrimax pharma tirosint amneal unithroid pfizer levoxyl well
gener market particip amneal sandoz alvogen lupin launch gener
januari gener account rx written levothyroxin sodium per
iqvia data note tirosint somewhat differ product gel
capsul oppos tablet though incorpor activ ingredi
substitutability/bioequival standard surround levothyroxin gener also
surprisingli complex garden varieti gener oral solid market three
refer list drug rld tablet form levothyroxin sodium synthroid unithroid
levoxyl bioequival must demonstr three order gain ab-
rate brand product ab-rat three product lupin also ab-rat
three rld sandoz two ab rate amneal one
summari levothyroxin ab rate refer list drug rld
entri lupin product earli price dynam clearli becom
challeng amneal commentari variou point underscor challeng
dynam amneal enter levothyroxin market late per distribut agreement
privately-held jerom steven pharmaceut jsp partner amneal jsp make
product own file agreement given lannett cover
exclus distribut right
jsp product
expir amneal think way mark levothyroxin space would
becom significantli crowd distribut gener could sourc sustain
revenu signific cash gener challeng even one entrant lupin
case price dynam still becom markedli challeng given power
buyer consortium retail gener market
asid lannett aim re-ent levothyroxin market anoth product per
distribut agreement sign neolpharma juli state publicli
believ could market levothyroxin tablet product sometim put
anoth way competit dynam continu bear watch note lupin gener
place sinc
page
ab rate refer list drugsynthroidunithroidlevoxylmylan genericyesyesyessandoz genericyesnoyesamn genericnoyesnolupin genericyesyesyesalvogen genericyesnono volum share inclus brand product volum share also
inclus brand
levothyroxin market volum brand gener
page
estrac cream launch first gener version allergan estrac cream estradiol
vagin cream vulvar vagin atrophi decemb notabl teva launch
gener product shortli thereaft market sinc becom even crowd
amneal enter estrac cream space gener april note share
estrac cream rx volum higher market particip
inclus allergan brand per iqvia data myl estrac gener product largest
sell gener compani
page
restasi still wait one file longer legal impedi
launch specif court appeal feder circuit washington
novemb affirm previou rule patent trial appeal board ptab
intellectu properti surround restasi invalid ground obvious plaintiff also
includ overweight teva teva neutral challeng associ
gener fairli complex specif ophthalm emuls form
immunomodulatori agent cyclosporin gener sens ophthalm solut far easier
copi ophthalm emuls good news still fda-approv
gener file tent approv
teva believ first-to-fil statu therefor entitl day gener
exclus teva notabl su fda forc fda essenti grant statu feder
district court reject lawsuit earli state teva disput fda
determin first-to-file/exclus statu abbrevi nda approv place
certainli clear gener market format occur certainli
chanc could find market gener convers chanc
hand gener approv rapid success without filer day
exclus point major price eros shortli gener market format larger point
restasi gener still much wild card note allergan
report restasi sale sale product first nine month
total brand dri eye product market consist two major player
restasi novarti xiidra lifitegrast ophthalm solut approv juli
develop origin commerci shire later acquir takeda
page
tecfidera file bear watch even though crowd file say
least report sale tecfidera annual around
accord sec file abbrevi nda file pend
gener version product said file petit patent trial
appeal board ptab seek inter part review ipr patent
expir februari orang book patent protect product expir late
june patent claim surround treatment multipl sclerosi daili
dose mg underli molecul mainten dose per prescrib
label argu patent invalid ground obvious small part
dosag fall within rang mg mg previous test
claim broadli speak magnitud efficaci pivot studi specif dose
mg novel find note ptab hear held novemb
decis like one consequenti headlin
potenti nearer-term opportun gener market format certainli sustain stream
cash flow nonetheless potenti short-term cash flow win
symbicort symbicort inhal combin corticosteroid budesonid long-
act beta agonist laba formoterol specif formul metered-dos inhal
mdi product
chronic obstruct pulmonari
diseas astrazeneca report net sale octob astrazeneca
initi litig regard anda file paragraph iv stay
prevent launch per hatch-waxman expir note
astrazeneca su patent
page
expir juli juli juli februari respect lastli note
teva also filer gener version symbicort litig versu astrazeneca case
also on-going
revlimid myl pursuit gener version celgen highest sell product inde one
highest sell anti-canc agent market certainli goe back long way celgen
report revlimid lenalidomid sale report global sale
period increas respect versu juli celgen
agre settl litig pay compani relat anti-trust lawsuit
file celgen file lawsuit alleg celgen refus make
suppli activ drug avail gener manufactur test
note celgen reach settlement natco pharma alvogen march
allow two compani distribut small-volum amount gener lenalidomid
 start march two compani abl sell gener product without
limit begin januari current awar one revlimid gener avail
certain smaller european market alvogen launch product earli
note actual psc estim base im sale data figur may exact
includ form epipen
report psc estim
page
sale sodium advair wixela acet transderm calcium doexpin hcl magnesium hcl oral decano inject sodium depakot er er glucophag er hcl er paxil gener gross gener net
biosimilar product either market clinic develop focu area
oncolog immunolog endocrinolog ophthalmolog compani long-stand
partnership india-bas biocon form major biosimilar pipelin
agreement biocon encompass fda-approv biosimilar neulasta
pegfilgrastim launch juli roch herceptin trastuzumab recent
launch decemb addit biosimilar develop part
partnership includ biosimilar abbvi humira adalimumab roch avastin bevacizumab
regeneron eylea aflibercept note partnership manufactur
includ momenta fujifilm kyowa kirin biolog revanc
compani report psc research
asset highlight blue partner biocon
asset highlight green orencia eylea partner momenta
botox partnership revanc
fulphila competit headwind bear watch becam first compani gain fda
approv biosimilar known fulphila neulasta pegfilgrastim
standard-of-car agent reduct incid infect associ febril
neutropenia due chemotherapi recent pegfilgrastim market consist
innov coheru note coheru cover udenyca approv
fda novemb novemb product account
pegfilgrastim sale report iqvia product account around sale per
iqvia sandoz ziextenzo becam latest market entrant gain approv novemb
though lost us penetr pegfilgrastim biosimilar grow around
overal pegfilgrastim sale report third parti month novemb compar
around end creat potenti rise tide lift boat paradigm
variou pegfilgrastim biosimilar tend believ crowd market becom
price eros play role would take view fulphila sale
posit grow
page
outsid note fulphila approv european medicin agenc
septemb addit biosimilar pegfilgrastim avail europ includ
ziextenzo mundipharma pelmeg accord healthcar pelgraz
herceptin trastuzumab biosimilar launch anoth potenti higher margin driver least
part go get crowd time recent launch ogivri
biosimilar roch intraven iv -administ herceptin trastuzumab specif
launch mg multi-dos vial mg single-dos vial ogivri second
herceptin biosimilar mg dose enter market amgen kanjinti launch juli
also launch dose biosimilar trazimera teva biosimilar herzuma
gain fda approv march decemb respect note neither
pfizer teva biosimilar launch though trazimera set launch februari
beyond note roch gain fda approv subcutan sc inject form
herceptin known hylecta februari ad anoth wrinkl broader trastuzumab
space clear enter highli competit space beyond
certainli clear kind penetr see biosimilar garden
varieti gener gener penetr well north market rel
said believ ogivri consequenti contributor north american
busi note roch report herceptin sale around
suggest public commentari herceptin product
annual sale gener neighborhood fulphila
page
mylan pipelin biosimilar develop via myriad partnership includ
biosimilar number blockbust product includ abbvi humira adalimumab roch
avastin bevacizumab regeneron eylea
avastin avastin monoclon antibodi act vascular endotheli growth factor
vegf time one largest sell target anti-canc agent
global note roch report avastin sale around global sale
around time-frame biocon state publicli phase
studi non-smal cell lung cancer nsclc met primari endpoint two compani plan
submit regulatori file us europ note amgen mvasi becam
first biosimilar avastin gain fda approv septemb launch juli
due litig versu roch pfizer avastin biosimilar zirabev gain fda approv june
launch product recent
humira humira world largest sell biolog sale global
sale time-frame per cover chri raymond
product inhibitor tumor necrosi factor-alpha tnf-alpha approv myriad
autoimmun condit note myl biosimilar known trade name hulio launch
eu octob state aim launch hulio per
settlement surprisingli larg number compani approv
pend file humira biosimilar though settlement place filer
knowledg refer exhibit detail
page
eylea develop eylea via partnership momenta cover daniel
brill biosimilar current phase studi file expect sometim eylea
approv fda wet age-rel macular degener macular edema due retin
vein occlus diabet macular edema diabet retinopathi regeneron/sanofi report
 sale product global sale
keep eye yupelri novemb partner threrav cover
tyler van buren gain fda approv yupelri revefenacin patient chronic
obstruct pulmonari diseas copd launch decemb product becam first
once-daili nebulizer-bas long-act muscarin antagonist lama launch copd
market note therav enter collabor
econom consist profit note june therav
expand term ex-u agreement includ china neighbor territori
accord therav copd patient use nebul mainten therapi though
around copd patient use nebul occas bronchodil treatment larger
point though much copd space consist inhaler-bas treatment hand-
held devic rel sizabl nich patient reli nebulizer-bas
treatment therav commerci infrastructur larg focus hospit set
inpati hospit discharge/transit home health paradigm commerci
infrastructur focus outpati set regard payer landscap therav
note perman j-code place cite institut formulari win late
equat account
week end around retail rx written yupelri compar
closer begin note weekli volum advers impact
shorten holiday week per iqvia sequenti rx growth versu
around rx written product
wholesal averag cost yupelri per month assum gross-to-net spread
estim net sale retail set base recent week rx volum
annual around
page
dymista anoth respiratory/allergi product sizabl contributor gain
dymista intranas formul antihistamin azelastin hydrochlorid
corticosteroid fluticason propion via acquisit meda sweden-bas pharmaceut
compani larg compos brand over-the-count over-the-counter product august
transact repres major shift away gener enabl greater geograph
diversif dymista one consequenti brand
ad global portfolio via transact addit product distribut
number territori includ eu russia new zealand began phase
clinic work china
accord iqvia data rx dymista first month around
decreas versu correspond period note sale per iqvia
annual around versu closer clearli priorit
geograph expans particularli given dymista patent expiri far away per
fda orang book patent expiri note settl
patent litig though launch date gener
page
begin reorgan busi three distinct busi segment
one off-pat brand gener busi busi collect part
upjohn entiti upjohn report revenu segment notabl
consid world largest pharmaceut compani oper china brand
portfolio consist product mani household name includ lyrica lipitor
norvasc celebrex viagra upjohn manufactur facil world-wide
compani produc api variou product notabl upjohn current key
brand lost exclus world major market except lyrica effexor
japan upjohn top five brand product lyrica lipitor norvasc celebrex viagra account
compani total revenu first nine month exclud lyrica
lost exclus juli upjohn top five brand still account
total revenu time-frame undoubtedli global organ one
real revenu concentr
page
page
lyricalipitornorvasccelebrexviagraunderli moleculepregabalinatorvastin calciumamlodipin besylatecelecoxibsildenafil citrateindicationneuropath pain postherpet neuralgia partial onset seizur fibromyalgiahigh cholesterol hypertens coronari arteri diseas chronic stabl angina chronic arthrit rheumatolog acut pain erectil dysfunctionyear approv loeslost exclus juli exclus japan decemb worldwideoff-pat worldwidelos exclus japan june upjohn revenu upjohn revenu
path sustain
latest color exposur china thought question china vast
market vein could repres signific opportun new entiti term
abil drive penetr gener product also question local compani
china gain greater foothold domest market say chines
pharmaceut industri anywher near kind matur seen indian pharmaceut
industri year could chang
per around total upjohn revenu first nine month gener
greater china region vein recent polici chang china name tender
system caus concern specif march china implement qualiti
consist evalu qce process reassess bioequival gener drug made
china end total molecul pass qce
addit current undergo qce registr importantli qce guidelin
product go tender process three substitut gener
pass qce way incentiv local gener compani carri in-hous
qce process end may chines regulatori bodi respons oversight
qce process accept review qce applic regard
beyond chines govern march china launch tender system requir
volume-bas procur molecul alreadi pass qce public hospit
major chines citi repres around third total chines pharmaceut
market basi polici creat bid process molecul
bidder actual four bidder septemb china expand
system nationwid modifi bid process percent sale volum may
guarante lowest three bidder process essenti creat race bottom
term price omin develop compani like upjohn alreadi signific
presenc rel higher margin asset notabl upjohn lipitor norvasc two
molecul includ tender process neither molecul success first bid
process bid local chines gener compani given dynam
reason assum least would expect see price pressur
key product declin sale china time refer revenu model upjohn
core brand detail new tender process like continu implement
road instanc chines govern plan implement new polici standard
reimburs price approv gener origin drug next two-to-thre year
put addit pressur price
thought trajectori upjohn brand asset
revenu model reflect pressur upjohn core brand product later
year china market well reflect view extent
asset commod product wouldnt case time
market
lyrica upjohn last brand asset lose exclus lyrica pregabalin
gabapentinoid mainstay anti-epilept drug well mainstay treatment
neuropath pain fibromyalgia wide use off-label rang set includ
psychiatr set unlik predecessor product neurontin gabapentin product
initi approv fda consist blockbust seller
small feat given blockbust small molecul agent mass market indic
harder come given realiti restrict payer landscap last decad
particularli past sever year
page
sale lyrica repres upjohn total world-wide
revenu footprint lyrica lost exclus juli sale drop
nine month end lyrica sale
correspond period world-wide sale
first nine month note lyrica lose exclus
japan decemb sale lyrica japan per total account
around upjohn total revenu year
lipitor obviou concern regard lipitor potenti pressur sale china given
signific contribut product upjohn overal china footprint lipitor gener
world-wide sale sale come china
first nine month lipitor sale china total account around total
upjohn revenu footprint sure grow given loss lyrica exclus
beyond china wonder see pressur sale product develop
emerg market instanc upjohn note sale discontinu saudi arabia though
also cite sale growth vietnam brazil possibl offset overal howev believ
product commodit global time
norvasc dynam anti-hypertens norvasc similar lipitor norvasc
gener world-wide sale come china around
total world-wide upjohn sale first nine month norvasc sale china
account around total upjohn revenu beyond china note sale
discontinu venezuela anoth product envis
commodit global scale
brand celebrex viagra non-steroid anti-inflammatori drug nsaid celebrex
noteworthi sinc set lose exclus japan june sale product
japan account around product total world-wide sale around
year note sale key brand like continu pressur given
myriad lose exclus recent year viagra decemb relpax
decemb celebrex novemb lastli anti-depress effexor repres
upjohn latest activ patent lose exclus japan septemb
page
report pjc estim
greenston gener segment upjohn total revenu
gener portfolio consist mix oral solid major product portfolio liquid
rang topic agent includ transderm product largest sell product categori
portfolio base iqvia sale clindamycin compani distribut oral
topic form topic form garner lion share sale anoth key product
author gener form depo provera medroxyprogesteron inject contracept
product lost exclus novemb amphastar neutral becam first
gener entrant market distribut brand know gener
market includ mylan gener one product divest due overlap
one notabl aspect busi licens agreement allergan regard
sale certain gener product agreement contribut revenu per
page
sale /other net salestot gross gener gener upjohn
total greenston revenu year greenston book revenu sale
gener agreement make profit share payment allergan octob
agreement allergan extend decemb partnership primarili
relat sale prescription-bas off-pat ophthalm product allergan legaci eye
care busi know approxim prescript eye care product greenston
report psc estim
page
sale gener gross gener net
michael goettler chief execut offic michael goettler current execut vice
presid year pharmaceut industri extens
commerci leadership experi live work multipl market region
asia/pacif europ mr goettler join part wyeth acquisit
held number senior leader role wyeth increas respons
across multipl therapeut area includ primari specialti care recent serv
global presid pfizer inflamm immunolog lead pfizer global five-billion-dollar
portfolio in-line medicin well late-stag earli develop research strategi
program span rheumatolog dermatolog gastroenterolog led pfizer
diseas initi compani commerci move gene therapi prior wyeth
michael held varieti senior role sanofi aventi us japan busi
develop e-business global market michael began career work hoechst
germani quickli move role increas respons includ execut vice
presid ceo hoechst marion roussel korea hold univers
texa austin graduat koblenz school corpor manag germani
prior join michael work hoechst aventi pharma sanofi
robert couri execut chairman robert couri current chairman
 couri first elect board director februari serv sinc
strateg advisor compani becam board vice chairman shortli
elect serv ceo septemb januari couri serv
execut chairman becam chairman june sinc couri led
compani seri transact total billion transform
one largest pharmaceut compani world
rajiv malik presid rajiv malik serv presid mylan sinc januari
also serv compani board director lead global commerci oper
activ compani prior current role presid malik held leadership posit
sinc januari acquir control stake matrix
laboratori limit prior acquisit malik matrix ceo establish matrix
key arv supplier develop market prior join matrix malik head
global develop regulatori sandoz initi start ranbaxi laboratori
rise head gener malik earn master degre pharmaceut
technolog punjab univers india process patent credit
overweight pt base ep discount risk includ
price competit risk gener product
overweight pt base ep discount risk includ
price pressur pressur competit entrant
teva neutral pt base ev/ebitda assum cash debt
share outstand risk includ copaxon competit gener
neutral pt base dilut ep estim discount
risk includ fda setback well pressur new gener entrant
page
viatri quarterli annual incom statement
million except ep
rest world
sale
sell gener administr
incom loss tax
expens revenu
sell gener administr
sell gener administr
proprietari piper sandler januari
current disclosur inform compani found http //www pipersandl com/researchdisclosur
